Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia
暂无分享,去创建一个
[1] M. Ghannoum,et al. Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method , 2008, Antimicrobial Agents and Chemotherapy.
[2] J. Donnelly,et al. Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and Candidemia , 2007, Antimicrobial Agents and Chemotherapy.
[3] A. Colombo,et al. Prospective Observational Study of Candidemia in São Paulo, Brazil: Incidence Rate, Epidemiology, and Predictors of Mortality , 2007, Infection Control & Hospital Epidemiology.
[4] K. Garey,et al. Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia , 2006, Antimicrobial Agents and Chemotherapy.
[5] C. Clancy,et al. In Vitro Susceptibility of Breakthrough Candida Bloodstream Isolates Correlates with Daily and Cumulative Doses of Fluconazole , 2006, Antimicrobial Agents and Chemotherapy.
[6] D. Andes. Pharmacokinetics and pharmacodynamics of antifungals. , 2006, Infectious disease clinics of North America.
[7] K. Garey,et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] M. Pfaller,et al. Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing , 2006, Clinical Microbiology Reviews.
[9] D. Snydman,et al. Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia , 2005, Antimicrobial Agents and Chemotherapy.
[10] J. Baddley,et al. Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. , 2005, Diagnostic microbiology and infectious disease.
[11] J. Baddley,et al. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. , 2004, Diagnostic microbiology and infectious disease.
[12] S. Ichiyama,et al. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection , 2004, European Journal of Clinical Microbiology and Infectious Diseases.
[13] D. Andes,et al. In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.
[14] M. Arendrup,et al. In Vivo Pathogenicity of Eight Medically Relevant Candida Species in an Animal Model , 2002, Infection.
[15] M. Ghannoum,et al. Antifungal Susceptibility Testing: Practical Aspects and Current Challenges , 2001, Clinical Microbiology Reviews.
[16] L. See,et al. Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe CandidaInfections Treated with Fluconazole , 2000, Antimicrobial Agents and Chemotherapy.
[17] J. Sobel,et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] D. Andes,et al. Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model , 1999, Antimicrobial Agents and Chemotherapy.
[19] Michael H. Miller,et al. Pharmacokinetic Studies of Fluconazole in Rabbits Characterizing Doses Which Achieve Peak Levels in Serum and Area under the Concentration-Time Curve Values Which Mimic Those of High-Dose Fluconazole in Humans , 1998, Antimicrobial Agents and Chemotherapy.
[20] Michael H. Miller,et al. Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.
[21] O. Ozdemir,et al. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] M. Ghannoum,et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] M. Levenstein,et al. A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .
[24] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[25] Clinical,et al. Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .
[26] Hakuo Takahashi,et al. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia , 2006, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[27] J. Billé,et al. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? , 2000, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.